Identifying barriers associated with enrollment of patients with lung cancer into clinical trials

Clinical Lung Cancer

Volumn 14, Issue 1, 2013, Pages 14-18

  Horn, Leora ^a   Keedy, Vicki L ^a   Campbell, Norma ^a   Garcia, Gabe ^a   Hayes, Amy ^a   Spencer, Brady ^a   Carbone, David P ^a   Sandler, Alan ^b   Johnson, David H ^c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Eligibility; Enrollment; NSCLC; SCLC

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CLINICAL TRIAL (TOPIC); ENROLLMENT; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT ATTITUDE; PATIENT CARE; PATIENT ENROLLMENT; REGISTRATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; COMORBIDITY; ELIGIBILITY DETERMINATION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMALL CELL LUNG CARCINOMA; STATISTICS, NONPARAMETRIC; TREATMENT REFUSAL;

EID: 84871576568     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.03.008     Document Type: Article

References (25)

1. H.A. Tejeda, S.B. Green, E.L. Trimble Representation of African-Americans, hispanics, and whites in National Cancer Institute cancer treatment trials J Natl Cancer Inst 88 1996 812 816
2. L.F. Hutchins, J.M. Unger, J.J. Crowley Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 1999 2061 2067
3. J.M. Peppercorn, J.C. Weeks, E.F. Cook Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review Lancet 363 2004 263 270
4. W.B. Sateren, E.L. Trimble, J. Abrams How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials J Clin Oncol 20 2002 2109 2117
5. J.H. Stewart, A.G. Bertoni, J.L. Staten Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities Ann Surg Oncol 14 2007 3328 3334
6. V.H. Murthy, H.M. Krumholz, C.P. Gross Participation in cancer clinical trials: race-, sex-, and age-based disparities JAMA 291 2004 2720 2726
7. C. Mengis, S. Aebi, A. Tobler Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials J Clin Oncol 21 2003 3933 3939
8. J.H. Lewis, M.L. Kilgore, D.P. Goldman Participation of patients 65 years of age or older in cancer clinical trials J Clin Oncol 21 2003 1383 1389
9. P.A. Bunn Jr, R. Lilenbaum Chemotherapy for elderly patients with advanced non-small-cell lung cancer J Natl Cancer Inst 95 2003 341 343
10. A. Jemal, R. Siegel, E. Ward Cancer statistics CA Cancer J Clin 2008 2008 71 96
11. L.A. Newman, T. Hurd, M. Leitch A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group J Am Coll Surg 199 2004 644 651
12. NIH Revitalization Act of 1993 Public Law 103-13 June 10, 1993 http://grants.nih.gov/grants/olaw/pl103-43.pdf Accessed: April 30, 2012
13. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
14. R. Pérez-Soler, A. Chachoua, L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
15. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial) [corrected] J Clin Oncol 21 2003 2237 2246
16. V. Cottin, D. Arpin, C. Lasset Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole Ann Oncol 10 1999 809 815
17. P.N. Lara Jr, R. Higdon, N. Lim Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment J Clin Oncol 19 2001 1728 1733
18. R.S. Go, K.A. Frisby, J.A. Lee Clinical trial accrual among new cancer patients at a community-based cancer center Cancer 106 2006 426 433
19. M.S. Simon, W. Du, L. Flaherty Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center J Clin Oncol 22 2004 2046 2052
20. C. Tournoux, S. Katsahian, S. Chevret Factors influencing inclusion of patients with malignancies in clinical trials Cancer 106 2006 258 270
21. R.S. Mannel, J.L. Walker, N. Gould Impact of individual physicians on enrollment of patients into clinical trials Am J Clin Oncol 26 2003 171 173
22. K. Antman, D. Amato, W. Wood Selection bias in clinical trials J Clin Oncol 3 1985 1142 1147
23. C.A. Townsley, K. Naidoo, G.R. Pond Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns J Clin Oncol 21 2003 4627 4635
24. M.L. Janssen-Heijnen, R.M. Schipper, P.P. Razenberg Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study Lung Cancer 21 1998 105 113
25. R.C. Lilenbaum, J. Cashy, T.A. Hensing Prevalence of poor performance status in lung cancer patients: implications for research J Thorac Oncol 3 2008 125 129